SS
TSHA icon

SBI Securities’s Taysha Gene Therapies TSHA Stock Holding History

SBI Securities’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.9K Buy
3,065
+3,050
+20,333% +$18K ﹤0.01% 1532
2026
Q1 		$67 Hold
15
– – ﹤0.01% 3519
2025
Q4 		$83 Sell
15
-1
-6% -$5 ﹤0.01% 3462
2025
Q3 		$52 Sell
16
-64
-80% -$181 ﹤0.01% 3706
2025
Q2 		$185 Hold
80
– – ﹤0.01% 3341
2025
Q1 		$111 Hold
80
– – ﹤0.01% 3411
2024
Q4 		$138 Buy
+80
New +$166 ﹤0.01% 3365

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SBI Securities's TSHA Position: Q2 2026 in Review

SBI Securities increased its Taysha Gene Therapies (TSHA) stake by 20,333% in Q2 2026, buying an estimated $18K and bringing the position to 3,065 shares worth $20.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1532.

SBI Securities first reported a position in TSHA in Q4 2024 and has held it in 7 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • SBI Securities held 3,065 shares of Taysha Gene Therapies worth $20.9K as of Q2 2026.
  • SBI Securities bought 3,050 Taysha Gene Therapies shares in Q2 2026, an estimated $18K.
  • Taysha Gene Therapies made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1532 holding.
  • SBI Securities first reported a position in Taysha Gene Therapies in Q4 2024 and has held it in 7 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.